Dietary supplementation with L-arginine: Modulation of tumour-infiltrating lymphocytes in patients with colorectal cancer

British Journal of Surgery

Volumn 84, Issue 2, 1997, Pages 238-241

  Heys, S D ^a,b   Segar, A ^a   Payne, S ^a   Bruce, D M ^a   Kernohan, N ^a   Eremin, O ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; ARGININE; COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KILLER CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; RECEPTORS, IGG;

EID: 0031015846     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800840229     Document Type: Article

References (31)

1. Cochran AJ. Histology and prognosis in malignant melanoma. J Pathol 1969; 97: 459-68.
2. Watt AG, House AK. Colonic carcinoma: a quantitative assessment of lymphocyte infiltration at the periphery of colonic tumors related to prognosis. Cancer 1978; 41: 279-82.
3. Kreider JW, Bartlett GL, Butkiewicz BL. Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis. Cancer Metastasis Rev 1984; 3: 53-74.
4. Svennig JL, Lunde OC, Holter J, Bjorgsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 1984; 49: 375-7.
5. Vose BM, Moore M. Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol 1985; 22: 27-40.
6. Csiba A, Whitwell HL, Moore M. Distribution of histocompatibility and leucocyte differentiation antigens in normal colon and benign and malignant colonic neoplasms. Br J Cancer 1984; 50: 699-709.
7. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187-375.
8. Heo DS, Whiteside TJ, Johnson JT, Chen K, Barnes EL, Herberman RB. Long term interleukin 2 dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes (TIL) from human squamous cell carcinomas of the head and neck. Cancer Res 1987; 47: 6353-362.
9. Whiteside TJ. Functional characteristics of fresh TIL. In: Whiteside TJ, ed. Tumor-infiltrating Lymphocytes in Human Malignancies. Austin, Texas: RG Landes, 1993: 52-66.
10. Rosenberg SA, Spiess P, Lafreniere R. A new approach to adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318-21.
11. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319: 1676-80.
12. Brittenden J, Heys SD, Ross J, Park KGM, Eremin O. Nutritional pharmacology: effects of L-arginine on host defences, response to trauma and tumour growth. Clin Sci 1994; 86: 123-32.
13. Park KGM, Hayes OD, Sewell H, Garlick PJ, Eremin O. Stimulation of lymphocyte natural cytotoxicity by L-arginine. Lancet 1991; 337: 645-6.
14. Brittenden J, Heys SD, Ross J, Park KGM, Eremin O. Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy: effects of L-arginine supplementation. Eur J Surg Oncol 1994; 20: 467-72.
15. Van Noorden S. Tissue preparation and immunological staining techniques for light microscopy. In: Polak J and Van Noorden S, eds. Immunocytochemistry: Modern Methods and Applications. 2nd ed. Bristol: Wright, 1986; 26-53.
16. Ralfkiaer E, Hou-Jensen K, Gatter KC, Drzewiecki KT, Mason DY. Immunohistochemical analysis of the lymphoid infiltrate in cutaneous malignant melanomas. Virchows Arch A Pathol Anat Histopathol 1987; 410: 355-61.
17. Prehn RT, Prehn LM. The flip side of tumour immunity. Arch Surg 1989; 124: 102-6.
18. Rosenberg SA, Lotze MT, Yang JC et al. Experience with use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-83.
19. Fisher B, Packard BS, Read EJ et al. Tumor localization of adoptively transferred indium-111 labelled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989; 7: 250-61.
20. 111indium labelled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Cancer 1994; 73: 1731-7.
21. Whiteside TJ. Adoptive therapy with TIL. In: Whiteside TJ, ed. Tumor-infiltrating Lymphocytes in Human Malignancies. Austin, Texas: RG Landes, 1993: 89-110.
22. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982; 243: C212-21.
23. Ffloyd JC, Fajans SS, Conn JW, Knope RF, Rull J. Stimulation of insulin secretion by amino acids. J Clin Invest 1996; 45: 1487-502.
24. Weir CG, Samois E, Loo Y, Patel YC, Gabby KH. Somatostatin and pancreatic polypeptide secretion: effects of glucagon, insulin and arginine. Diabetes 1979; 28: 35-40.
25. Merimee TJ, Lillcrap DA, Rabinowitz D. Effect of arginine on serum levels of human growth hormone. Lancet 1965; ii: 668-70.
26. Efron DT, Kirk SJ, Regan M et al. Nitric oxide generation from L-arginine is required for optimal peripheral blood lymphocyte DNA synthesis. Surgery 1991; 110: 327-34.
27. Roder JC, Klein M. Target-effector interaction in natural killer cell system. IV. Modulation by cyclic nucleotides. J Immunol 1979; 123: 2785-90.
28. Whelan MM, Bankhurst AD. Effects of beta-adrenergic receptor activation, cholera toxin and forskolin on human natural killer cell function. Biochem J 1990; 272: 327-31.
29. Brittenden J, Ross J, Heys SD et al. In vitro modulation of natural cytotoxicity by nitric oxide synthase inhibitors. Br J Surg 1993; 80: 1478 (Abstract).
30. Reynolds JV, Daly MD, Shou J, Sigal R, Ziegler MM, Naji A. Immunological effects of arginine supplementation in tumor bearing and non tumor bearing hosts. Ann Surg 1990; 211: 202-9.
31. Rothlein R, Czaikowski M, O'Neill MM, Martin SD, Mainolfi E, Merrluzzi VJ. Induction of intercellular adhesion molecule-1 on primary and continuous cell lines by proinflammatory cytokines. J Immunol 1988; 141: 1665-9.